
ZYME • NYSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ZYME in your mock portfolio yet.
Zymeworks remains unprofitable, as indicated by its negative EPS and PE ratio. The current earnings profile suggests the company is still in an investment and development phase, with no clear evidence yet of sustainable profitability. From a pure fundamentals standpoint, the stock is dependent on future growth expectations rather than current earnings strength.
The stock is trading at $26.87, modestly higher over the last month and significantly above its 200‑day moving average of $15.67, signaling a strong intermediate‑term uptrend. An RSI of 63.60 indicates positive momentum that is not yet in extreme overbought territory, though it is approaching that zone. Overall, technicals lean bullish, suggesting buyers are in control but the stock is becoming more extended.
Alternative data for Zymeworks is mixed: web traffic is flat, job postings are down, and social media followings are growing only slightly. The decline in job openings could signal either increased cost discipline or a slowdown in expansion. Overall, these signals do not strongly confirm or contradict the bullish technical picture, pointing instead to a cautious or steady operational posture.
Zymeworks shows a strong bullish technical setup but remains fundamentally unprofitable, with alternative data pointing to stability rather than aggressive growth. The overall picture is balanced: momentum traders may view the trend favorably, while fundamental investors may be cautious given negative earnings and only modest external growth signals.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: